Dana-Farber Cancer Institute is running a clinical trial to test drugs called Obinutuzumab and Ibrutinib to treat chronic lymphocytic leukemia. This research study is evaluating a combination of two drugs, ibrutinib and obinutuzumab, as a possible treatment for Chronic Lymphocytic Leukemia (CLL).
The drugs are Obinutuzumab and Ibrutinib.
| Study Type : | Interventional (Clinical Trial) |
| Estimated Enrollment : | 50 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | None (Open Label) |
| Primary Purpose: | Treatment |
| Official Title: | A Phase Ib Study of Ibrutinib in Combination With Obinutuzumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia |
| Actual Study Start Date : | December 2015 |
| Estimated Primary Completion Date : | December 2018 |
| Estimated Study Completion Date : | August 2021 |
For enrollment please visit www.clinicaltrials.gov.
